Study (year)	Clinical trial identified	Phase	Severity	Treatment regimens	Baseline PASI score,mean (SD)/median (range)	No. of Patients	Men, No. (%)	Age (years), mean (SD)	Duration of treatment	Outcomes
K. Papp, et al 2018	NCT02931838	Phase IIb	Moderate to severe	Deucravacitinib 12 mg QD	18 (6)	44	30 (68)	46.6 (11.6)	12w	PGA 0/1; PASI-75; AEs;
				Deucravacitinib 6 mg BID	18 (5)	45	35 (78)	42.8 (12.9)		
				Deucravacitinib 3 mg BID	18 (6)	45	26 (58)	45.6 (15.1)		
				Deucravacitinib 3 mg QD	18 (6)	44	30 (68)	45.0 (13.8)		
				Deucravacitinib 3 mg QOD	17 (4)	44	36 (82)	41.0 (11.8)		
				Placebo	19 (6)	45	37 (82)	46.4 (11.9)		
A.W. Armstrong, et al 2023	NCT03624127	Phase III	Moderate to severe	Deucravacitinib 6 mg QD	21.8 (8.6)	332	230 (69.3)	45.9 (13.7)	16w	PGA 0/1; PASI-75; AEs;
				Apremilast 30 mg BID	21.4 (9.0)	168	110 (65.5)	44.7 (12.1)		
				Placebo	20.7 (8.0)	166	113 (68.1)	47.9 (14.0)		
B. Strober, et al 2023	NCT03611751	Phase III	Moderate to severe	Deucravacitinib 6 mg QD	20.7 (7.5)	511	336 (65.8)	46.9 (13.4)	16w	PGA0/1; PASI-75; AEs;
				Apremilast 30 mg BID	21.6 (8.4)	254	157 (61.8)	46.4 (13.3)		
				Placebo	21.1 (9.0)	255	181 (71.0)	47.3 (13.6)		
Bristol-Myers Squibb, et al	NCT04167462	Phase III	Moderate to severe	Deucravacitinib 6 mg QD	NA	146	123 (84.2)	40.3 (12.2)	16w	PGA 0/1; PASI-75; AEs;
				Placebo		74	57 (77.0)	41.2 (12.3)		
S.B. Forman,et al 2020	NCT02969018	Phase IIa	Moderate to severe	Brepocitinib 30 mg QD	19.1 (5.9)	29	19 (65.5)	44.2 (10.9)	12w	PASI-75; AEs;
				Placebo	19.6 (7.6)	23	19 (82.6)	50.3 (12.2)		
C.Tehlirian, et al, 2022	NCT03895372	Phase IIb	Moderate to severe	Ropsacitinib 50 mg QD	19.5 (5.0)	22	15 (68.2)	43.1 (14.5)	16w	PGA 0/1; PASI-75; AEs;
				Ropsacitinib 100 mg QD	24.7 (10.3)	23	16 (69.6)	41.8 (12.4)		
				Ropsacitinib 200 mg QD	24.3 (11.6)	45	26 (57.8)	45.0 (13.0)		
				Ropsacitinib 400 mg QD	23.7 (11.0)	43	35 (81.4)	45.2 (12.2)		
				Placebo	21.9 (10.7)	45	30 (66.7)	46.5 (12.1)		
J. Krueger, et al 2016	NCT01710046	Phase IIa	Moderate to severe	Tofacitinib 10mg BID	21.9 (8.6)	9	7 (77.8)	45.2(11.3)	12w	PGA 0/1; PASI-75; AEs;
				Placebo	23.3 (9.8)	3	1 (33.3)	46.7 (21.5)		
J.Z. Zhang, et al 2017	NCT01815424	Phase III	Moderate to severe	Tofacitinib 5 mg BID	25.3 (10.2)	88	65 (73.9)	40.7 (11.3)	16w	PGA 0/1; PASI-75; AEs;
				Tofacitinib 10 mg BID	25.3 (9.1)	90	67 (74.4)	41.0 (12.0)		
				Placebo	26.1 (9.5)	88	62 (70.5)	41.7 (13.7)		
K. Papp, et al 2012	NCT00678210	Phase IIb	Moderate to severe	Tofacitinib 2 mg BID	21.5 (6.7)	49	29 (59.2)	45.7 (13.8)	12w	PGA 0/1 PASI-75; AEs;
				Tofacitinib 5 mg BID	21.2 (8.1)	49	29 (59.2)	44.0 (12.6)		
				Tofacitinib 15 mg BID	22.6 (10.33)	49	31 (63.3)	43.6 (15.6)		
				Placebo	21.5 (7.1)	50	36 (72.0)	43.9 (13.0)		
Bachelez, et al 2015	NCT01241591	Phase III	Moderate to severe	Tofacitinib 5 mg BID	21.0 (12.0-56.3)	329	236 (71.7)	44.0 (12.1)	12w	PGA 0/1 PASI-75; AEs;
				Tofacitinib 10 mg BID	21.0 (12.0-62.3)	330	238 (72.1)	43.6 (12.6)		
				Placebo	19.5 (12.4-54.6)	107	71 (66.3)	46.1 (13.4)		

K. Papp, et al 2015	NCT01276639	Phase III	Moderate to severe	Tofacitinib 5 mg BID	NA	363	261 (71.9)	45.6 (13.4)	16w	PGA 0/1 PASI-75; AEs;
				Tofacitinib 10 mg BID		360	261 (72.5)	45.2 (12.8)		
				Placebo		177	121 (68.4)	45.0 (12.6)		
K. Papp, et al 2015	NCT01309737	Phase III	Moderate to severe	Tofacitinib 5 mg BID	NA	382	268 (70.2)	45.9 (12.9)	16w	PGA 0/1 PASI-75; AEs;
				Tofacitinib 10 mg BID		381	257 (67.5)	44.3 (13.0)		
				Placebo		196	123 (62.8)	44.8 (12.6)		
Ludbrook, et al 2016	NCT01782664	Phase II	Moderate to severe	Solcitinib 100 mg BID	16.8 (12.2-34.4)	15	10 (66.7)	43.5 (11.8)	12w	PGA 0/1 PASI-75; AEs;
				Solcitinib 200 mg BID	17.35 (12.0-39.6)	16	10 (55.6)	47.7 (12.4)		
				Solcitinib 400 mg BID	15.3 (12.4-27.0)	14	9 (45.0)	42.0 (11.7)		
				Placebo	15.9 (12.0-33.2)	14	9 (64.3)	46.5 (11.1)		
K. Papp, et al 2016	NCT01490632	Phase IIb	Moderate to severe	Baricitinib 2 mg QD	21.4 (11.1)	32	23 (71.9)	47.8 (15.2)	12w	PGA 0/1 PASI-75; AEs;
				Baricitinib 4 mg QD	20.6 (9.4)	72	54 (75.0)	47.2 (11.7)		
				Baricitinib 8 mg QD	20.2 (7.8)	64	46 (71.9)	47.4 (15.8)		
				Baricitinib 10 mg QD	19.0 (6.2)	69	51 (73.9)	47.4 (10.4)		
				Placebo	19.1 (6.8)	34	23 (67.6)	46.7 (15.1)		
Vera M R Heydendael, et al 2003	/	Phase III	Moderate to severe	Methotrexate 15-22.5 mg QW	13.4 (3.6)	43	28 (65.1)	41.6 (13.0)	16w	PASI-75; AEs;
				Cyclosporine 3–5 mg/kg/day	14.0 (6.6)	42	29 (69.0)	38.3 (12.4)		
J-H Saurat, et al 2007	NCT00235820	Phase III	Moderate to severe	Methotrexate 7.5-25 mg QW	20.2 (7.5)	108	70 (64.8)	42.9 (12.6)	16w	PGA 0/1; PASI-75; AEs;
				Placebo	19.2 (6.9)	53	35 (66)	40.7 (11.4)		
S. F. Arani, et al 2011	/	Phase III	Moderate to severe	Methotrexate 5-15 mg QW	14.7 (3.0)	27	16 (59)	41 (14.0)	12w	PASI-75; AEs;
				Fumarates 30-120 mg	18.0 (6.9)	27	20 (74)	43 (16.0)		
K. Papp, et al 2015	NCT01194219	Phase III	Moderate to severe	Apremilast 30 mg BID	18.7 (7.2)	562	379 (67.4)	45.8 (13.1)	16w	PGA 0/1; PASI-75; AEs;
				Placebo	19.4 (7.4)	282	194 (68.8)	46.5 (12.7)		
K. Papp, et al 2012	NCT00773734	Phase IIb	Moderate to severe	Apremilast 30 mg BID	19.1 (7.1)	88	50 (57.0)	44.1 (14.7)	16w	PGA 0/1; PASI-75; AEs;
				Placebo	18.1 (5.7)	88	53 (60.0)	44.1 (13.7)		
C. Paul, et al 2015	NCT01232283	Phase III	Moderate to severe	Apremilast 30 mg BID	18.9 (7.1)	274	176 (64.2)	45.3 (12.1)	16w	PGA 0/1; PASI-75; AEs;
				Placebo	20.0 (8.0)	137	100 (73.0)	45.7 (13.4)		

eTable 1 Characteristics of included studies.